Impact of ileostomy in the adjuvant treatment of colorectal cancer stages II-III

Abstract

Investigator-assessed median PFS per RECIST was 6.9 months (95% CI, 5.9-12.7). ORR per RECIST was 23.8 % (95% CI, in the total population. The sunitinib rechallenge safety profile was as expected, with no new adverse events reported. The most common treatment-related AEs neutropenia (42.8%) and diarrhoea (33.2%). Conclusion: Sunitinib rechallenge is an efficacious and safe treatment option with potential clinical benefit in patients with advanced/metastatic, well-differentiated, panNETs. Disease progression with prior treatment with sunitinib may not be associated with complete or irreversible resistance to therapy. AEs were consistent with the known safety profile of sunitinib, therefore sunitinib rechallenge could represent a reasonable treatment option.